Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-01
Trial Details
NCT Number NCT07321678
Lead Sponsor Ascletis Pharma (China) Co., Limited
Conditions T2DM (Type 2 Diabetes Mellitus)
Enrollment 100 participants
Start Date 2026-01-22
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-30